A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
QI-019B represents a novel CAR-T therapy targeting both BCMA and CD19, indicating a dual mechanism that may enhance efficacy in treating relapsed/refractory multiple myeloma (MM). The trial is sponsored by the Institute of Hematology & Blood Diseases Hospital in China, with an estimated enrollment of 24 patients. Given the increasing prevalence of MM and the limitations of current therapies, QI-019B could capture significant market share if proven effective. The competitive landscape includes established CAR-T therapies, such as those targeting BCMA alone, and emerging therapies targeting multiple antigens. Diligence should focus on the safety profile, potential for combination therapies, and regulatory pathways in China and globally.
Indication: Multiple Myeloma (MM)
Modality: gene therapy
Target: BCMA/CD19-targeted CAR-T cells
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCMA/CD19-targeted CAR-T cells
View original source fields
Condition raw: Multiple Myeloma (MM)
Condition normalized: Multiple Myeloma (MM)
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: BCMA/CD19-targeted CAR-T cells
Target normalized: BCMA/CD19-targeted CAR-T cells